J&J invests in “cell-free” cartilage repair technology

JNJ LEADS $15 MILLION FUNDING FOR INNOVATIVE CARTILAGE TECHNOLOGY (Orthopedics This Week) website.. http://www.cartiheal.com/ Johnson & Johnson Innovation (JJDC investors) joins a blue chip list of venture investors including Elron, Accelmed, Access Medical Ventures, and Peregrine Ventures to fund an innovative cartilage repair technology called Agili-C and a promising young Israeli company named CartiHeal, Ltd. Agili-C, the technology that has attracted these top venture investors, is a calcium carbonite and HA (hyaluronic acid) implant that has been shown in several post-marketing studies (phase IV studies) to provide significant improvement in knee pain level, as well as reduction in related symptoms. Investigators who reviewed MRIs and histological findings of joints with an Agili-C implant found regeneration of hyaline cartilage and its underlying subchondral bone. The key to Agili-C is a novel (to orthopedics) type of calcium carbonate named Aragonite. Aragonite is, one of the two common, naturally occurring, crystal forms of calcium carbonate, CaCO3 (the other form being the mineral calcite), which is formed by biological and physical processes, including precipitation f...


Unlock the full article and exclusive OrthoStreams insights: in-depth analyses, hot startups, trends, market intel, and Daily Newsletter—for just $1/day.
Subscribe Now—Up your Game !
 

Scroll to Top